Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Research output: Contribution to journal › Review › Research › peer-review
The present meta-analysis evaluated the efficacy and safety of empagliflozin + linagliptin combination compared with either monotherapy [n=6 randomized controlled trials; 2857 adults with type 2 diabetes (T2DM) on diet + exercise +/- metformin; 39.7% women; mean age: 54.6-59.9 years]. The combination of empagliflozin 10 mg + linagliptin 5 mg led to significantly greater reductions in glycated haemoglobin (HbA1c) compared with either drug alone over 24 weeks: weighted mean difference [WMD; -0.72%, 95% confidence interval (CI): -1.04, -0.40], and fasting plasma glucose (-1.60 mmol/L 95% CI: -2.21, -1.00). Similar results were observed when empagliflozin 25 mg + linagliptin 5 mg was compared with linagliptin 5 mg monotherapy or with empagliflozin 10 or 25 mg monotherapy. Patients with T2DM treated with the drug combination had more than three times higher likelihood of achieving HbA1c
Original language | English |
---|---|
Journal | Diabetes, Obesity and Metabolism |
Volume | 22 |
Issue number | 6 |
Pages (from-to) | 1001-1005 |
Number of pages | 5 |
ISSN | 1462-8902 |
DOIs | |
Publication status | Published - 2020 |
- efficacy, Empagliflozin, fixed-dose combination, glycated haemoglobin, linagliptin, safety, weight, meta-analysis, SGLT-2 INHIBITOR, DPP-4 INHIBITOR, THERAPY, GENITOURINARY
Research areas
ID: 246092873